The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Ranitidine 50 mg/2 ml Solution for Injection and Infusion

Alliance Pharma (Ireland) LimitedPA2325/013/001

Main Information

Trade NameRanitidine 50 mg/2 ml Solution for Injection and Infusion
Active SubstancesRanitidine hydrochloride
Dosage FormSolution for injection/infusion
Licence HolderAlliance Pharma (Ireland) Limited
Licence NumberPA2325/013/001

Group Information

ATC CodeA02BA H2-receptor antagonists
A02BA03 famotidine


License statusWithdrawn
Withdrawn Date17/03/2023
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusNot marketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back